Debra Tonetti
Professor of Pharmacology, College of Pharmacy - Pharmaceutical Sciences
Leader, Breast Cancer Working Group, UI Cancer Center, University of Illinois at Chicago
Email:
Related Sites:
About Heading link
Teaching and Supervision Heading link
PSCI Ph.D. Thesis Research (PSCI 599), 1/9/2023 – 4/28/2023
PDAT 9: Hematology/Oncology (PHAR 509), 1/9/2023 – 4/28/2023
PDAT 9: Hematology/Oncology (PHAR 509), 1/9/2023 – 4/28/2023
PDAT 9: Hematology/Oncology (PHAR 509), 1/9/2023 – 4/28/2023
PDAT 9: Hematology/Oncology (PHAR 509), 1/9/2023 – 4/28/2023
PDAT 9: Hematology/Oncology (PHAR 509), 1/9/2023 – 4/28/2023
PDAT 9: Hematology/Oncology (PHAR 509), 1/9/2023 – 4/28/2023
Special Proj Pharm Sci (PSCI 390), 1/9/2023 – 4/28/2023
Undergrad Res Pharm Sci (PSCI 380), 1/9/2023 – 4/28/2023
Selected Grants
Finding cancer vulnerability through analysis of tolerant cell populations, Amer Lung Assn of Metropolitan Chicago., 7/1/2022 - 6/30/2024, Obligated Amount: $200000; Anticipated Amount: $200000
Estrogen Receptor and NFkB Crosstalk in Breast Cancer, National Institutes of Health (National Cancer Institute)., 2/1/2022 - 1/31/2027, Obligated Amount: $476979; Anticipated Amount: $2384909
Breast cancer virotherapy, National Institutes of Health (National Cancer Institute)., 4/1/2021 - 3/31/2024, Obligated Amount: $406658; Anticipated Amount: $411143
Targeting Serine Auxotrophy in Luminal Breast Cancer, National Institutes of Health (National Cancer Institute)., 3/1/2021 - 2/28/2026, Obligated Amount: $1071873; Anticipated Amount: $1798445
A Novel Biomarker for TTC-352 Therapy Development., 5/15/2019 - 4/30/2020, Obligated Amount: $1000000; No Anticipated Amount Set
A novel biomarker for TTC 352 cancer therapy development, University of Illinois DPI Seed Funding Program., 5/1/2019 - 4/30/2020, Obligated Amount: $100000; Anticipated Amount: $100000
A Novel BET Inhibitor for Breast Cancer Combinatiion Therapy, Chicago Biomedical Consortium., 1/1/2019 - 12/31/2019, Obligated Amount: $100000; Anticipated Amount: $100000
Development of PET Probe for ER+ Breast Cancer, UICentre-CCTS Inception Grant., 7/1/2018 - 6/30/2019, Obligated Amount: $12500; Anticipated Amount: $12500
Discovery of New Partners for Combination Therapy with G1T48, G1 Therapeutics Inc., 6/1/2017 - 5/31/2018, Obligated Amount: $350000; Anticipated Amount: $350000
Selected Publications
Pal, P, Millner, A, Semina, SE, Huggins, RJ, Running, L, Aga, DS, Tonetti, DA, Schiff, R, Greene, GL, Atilla-Gokcumen, GE, Frasor, J. (2022). Endocrine Therapy-Resistant Breast Cancer Cells Are More Sensitive to Ceramide Kinase Inhibition and Elevated Ceramide Levels Than Therapy-Sensitive Breast Cancer Cells. Cancers, 14, (10). doi:10.3390/cancers14102380.
Means-Powell, JA, Mayer, IA, Ismail-Khan, R, Del Valle, L, Tonetti, D, Abramson, VG, Sanders, MS, Lush, RM, Sorrentino, C, Majumder, S, Miele, L. (2022). A Phase Ib Dose Escalation Trial of RO4929097 (a γ-secretase inhibitor) in Combination with Exemestane in Patients with ER + Metastatic Breast Cancer (MBC). Clinical Breast Cancer, 22, (2), 103-114. doi:10.1016/j.clbc.2021.10.013.
Abderrahman, B, Maximov, PY, Curpan, RF, Fanning, SW, Hanspal, JS, Fan, P, Foulds, CE, Chen, Y, Malovannaya, A, Jain, A, Xiong, R, Greene, GL, Tonetti, DA, Thatcher, GRJ, Jordan, VC. (2021). Rapid induction of the unfolded protein response and apoptosis by estrogen mimic ttc-352 for the treatment of endocrine-resistant breast cancer. Molecular Cancer Therapeutics, 20, (1), 11-25. doi:10.1158/1535-7163.MCT-20-0563.
Abderrahman, B, Maximov, PY, Curpan, RF, Hanspal, JS, Fan, P, Xiong, R, Tonetti, DA, Thatcher, GRJ, Jordan, VC. (2020). Erratum: Pharmacology and molecular mechanisms of clinically relevant estrogen estetrol and estrogen mimic BMI-135 for the treatment of endocrine-resistant breast cancer (Molecular Pharmacology (2020) 98 (364-381) DOI: 10.1124/molpharm.120.000054). Molecular Pharmacology, 98, (4), 528. doi:10.1124/molpharm.120.000054err.
Dudek, AZ, Liu, LC, Fischer, JH, Wiley, EL, Sachdev, JC, Bleeker, J, Hurley, RW, Tonetti, DA, Thatcher, GRJ, Venuti, RP, O’Regan, RM. (2020). Phase 1 study of TTC-352 in patients with metastatic breast cancer progressing on endocrine and CDK4/6 inhibitor therapy. Breast Cancer Research and Treatment, 183, (3), 617-627. doi:10.1007/s10549-020-05787-z.
Li, Y, Zhao, J, Gutgesell, LM, Shen, Z, Ratia, K, Dye, K, Dubrovskyi, O, Zhao, H, Huang, F, Tonetti, DA, Thatcher, GRJ, Xiong, R. (2020). Novel Pyrrolopyridone Bromodomain and Extra-Terminal Motif (BET) Inhibitors Effective in Endocrine-Resistant ER+ Breast Cancer with Acquired Resistance to Fulvestrant and Palbociclib. Journal of Medicinal Chemistry, 63, (13), 7186-7210. doi:10.1021/acs.jmedchem.0c00456.
Andreano, KJ, Wardell, SE, Baker, JG, Desautels, TK, Baldi, R, Chao, CA, Heetderks, KA, Bae, Y, Xiong, R, Tonetti, DA, Gutgesell, LM, Zhao, J, Sorrentino, JA, Thompson, DA, Bisi, JE, Strum, JC, Thatcher, GRJ, Norris, JD. (2020). G1T48, an oral selective estrogen receptor degrader, and the CDK4/6 inhibitor lerociclib inhibit tumor growth in animal models of endocrine-resistant breast cancer. Breast Cancer Research and Treatment, 180, (3), 635-646. doi:10.1007/s10549-020-05575-9.
Abderrahman, B, Maximov, PY, Curpan, RF, Hanspal, JS, Fan, P, Xiong, R, Tonetti, DA, Thatcher, GRJ, Jordan, VC. (2020). Pharmacology and Molecular Mechanisms of Clinically Relevant Estrogen Estetrol and Estrogen Mimic BMI-135 for the Treatment of Endocrine-Resistant Breast Cancer (vol 98, pg 364, 2020). MOLECULAR PHARMACOLOGY, 98, (4), 528-528.
Lu, Y, Gutgesell, LM, Xiong, R, Zhao, J, Li, Y, Rosales, CI, Hollas, M, Shen, Z, Gordon-Blake, J, Dye, K, Wang, Y, Lee, S, Chen, H, He, D, Dubrovyskyii, O, Zhao, H, Huang, F, Lasek, AW, Tonetti, DA, Thatcher, GRJ. (2019). Design and Synthesis of Basic Selective Estrogen Receptor Degraders for Endocrine Therapy Resistant Breast Cancer. Journal of Medicinal Chemistry, 62, (24), 11301-11323. doi:10.1021/acs.jmedchem.9b01580.
Education
Degrees:
Doctor of Philosophy, Loyola University Chicago, United States, 1990
Master of Science, Loyola University Chicago, United States, 1985
Bachelor of Science, Northern Illinois University, United States, 1980
Postgraduate Training:
Enrico Fermi Postdoctoral Fellow, Argonne National Laboratory, United States, 1994